The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort.

Hdl Handle:
http://hdl.handle.net/10147/207835
Title:
The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort.
Authors:
Adams, Roisin; Craig, Benjamin M; Walsh, Cathal D; Veale, Douglas J; Bresnihan, Barry; FitzGerald, Oliver; Barry, Michael
Affiliation:
National Centre for Pharmacoeconomics, St. James Hospital, Dublin, Ireland., radams@stjames.ie
Citation:
Value Health. 2011 Sep-Oct;14(6):921-7. Epub 2011 Jul 8.
Journal:
Value in health : the journal of the International Society for Pharmacoeconomics , and Outcomes Research
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207835
DOI:
10.1016/j.jval.2011.03.002
PubMed ID:
21914514
Abstract:
BACKGROUND AND OBJECTIVE: It is well established that there are problems with the EQ-5D. This is due to the original scoring methods used and how negative time trade-off (TTO) values were treated. A revised scoring method has been published. This article applies this to an inflammatory arthritis cohort. The objective is to examine the impact of a revised scoring system for the EQ-5D (UK) TTO on the utility estimates and in the case of rheumatoid arthritis, to explore the impact of using different utility metrics on the incremental cost-effectiveness ratio (ICER) results of an economic model. METHODS: A total of 504 patients with inflammatory arthritis were rescored using revised EQ-5D scoring, which uses an episodic random utility model to deal with negative TTO values. Differences in utility scores were compared and the new mapping coefficients were obtained. These were then used in an economic model to examine the impact on the ICER. RESULTS: In rheumatoid arthritis, the overall change is less for the revised EQ-5D scoring than with the original EQ-5D (TTO) but greater than the SF-6D: EQ-5D UK -0.22 (95% confidence interval [CI] -0.30 to -0.15), revised EQ-5D UK -0.16 (95% CI -0.21 to -0.10) and SF-6D -0.08 (95% CI -0.11 to -0.05). A similar trend is seen in the psoriatic arthritis group. The economic model produced different ICERs, when different utility measures were used; EQ-5D (TTO) euro42,402, SF-6D euro111,788, and revised EQ-5D (TTO) euro57,747. CONCLUSION: In the context of inflammatory arthritis, this article demonstrates that a revised scoring for EQ-5D may have a significant impact on utility estimates and on the output of the economic model.
Language:
eng
MeSH:
Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Psoriatic/economics/*physiopathology/psychology; Arthritis, Rheumatoid/economics/*physiopathology/psychology; Cohort Studies; Cost-Benefit Analysis; Female; *Health Status; Humans; Male; Middle Aged; Models, Economic; Quality of Life; *Questionnaires; Young Adult
ISSN:
1524-4733 (Electronic); 1098-3015 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorAdams, Roisinen_GB
dc.contributor.authorCraig, Benjamin Men_GB
dc.contributor.authorWalsh, Cathal Den_GB
dc.contributor.authorVeale, Douglas Jen_GB
dc.contributor.authorBresnihan, Barryen_GB
dc.contributor.authorFitzGerald, Oliveren_GB
dc.contributor.authorBarry, Michaelen_GB
dc.date.accessioned2012-02-01T10:46:03Z-
dc.date.available2012-02-01T10:46:03Z-
dc.date.issued2012-02-01T10:46:03Z-
dc.identifier.citationValue Health. 2011 Sep-Oct;14(6):921-7. Epub 2011 Jul 8.en_GB
dc.identifier.issn1524-4733 (Electronic)en_GB
dc.identifier.issn1098-3015 (Linking)en_GB
dc.identifier.pmid21914514en_GB
dc.identifier.doi10.1016/j.jval.2011.03.002en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207835-
dc.description.abstractBACKGROUND AND OBJECTIVE: It is well established that there are problems with the EQ-5D. This is due to the original scoring methods used and how negative time trade-off (TTO) values were treated. A revised scoring method has been published. This article applies this to an inflammatory arthritis cohort. The objective is to examine the impact of a revised scoring system for the EQ-5D (UK) TTO on the utility estimates and in the case of rheumatoid arthritis, to explore the impact of using different utility metrics on the incremental cost-effectiveness ratio (ICER) results of an economic model. METHODS: A total of 504 patients with inflammatory arthritis were rescored using revised EQ-5D scoring, which uses an episodic random utility model to deal with negative TTO values. Differences in utility scores were compared and the new mapping coefficients were obtained. These were then used in an economic model to examine the impact on the ICER. RESULTS: In rheumatoid arthritis, the overall change is less for the revised EQ-5D scoring than with the original EQ-5D (TTO) but greater than the SF-6D: EQ-5D UK -0.22 (95% confidence interval [CI] -0.30 to -0.15), revised EQ-5D UK -0.16 (95% CI -0.21 to -0.10) and SF-6D -0.08 (95% CI -0.11 to -0.05). A similar trend is seen in the psoriatic arthritis group. The economic model produced different ICERs, when different utility measures were used; EQ-5D (TTO) euro42,402, SF-6D euro111,788, and revised EQ-5D (TTO) euro57,747. CONCLUSION: In the context of inflammatory arthritis, this article demonstrates that a revised scoring for EQ-5D may have a significant impact on utility estimates and on the output of the economic model.en_GB
dc.language.isoengen_GB
dc.subject.meshAdolescenten_GB
dc.subject.meshAdulten_GB
dc.subject.meshAgeden_GB
dc.subject.meshAged, 80 and overen_GB
dc.subject.meshArthritis, Psoriatic/economics/*physiopathology/psychologyen_GB
dc.subject.meshArthritis, Rheumatoid/economics/*physiopathology/psychologyen_GB
dc.subject.meshCohort Studiesen_GB
dc.subject.meshCost-Benefit Analysisen_GB
dc.subject.meshFemaleen_GB
dc.subject.mesh*Health Statusen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshModels, Economicen_GB
dc.subject.meshQuality of Lifeen_GB
dc.subject.mesh*Questionnairesen_GB
dc.subject.meshYoung Adulten_GB
dc.titleThe impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort.en_GB
dc.contributor.departmentNational Centre for Pharmacoeconomics, St. James Hospital, Dublin, Ireland., radams@stjames.ieen_GB
dc.identifier.journalValue in health : the journal of the International Society for Pharmacoeconomics , and Outcomes Researchen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.